Symbols

MGX

Metagenomi·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 0

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MGX

Metagenomi Therapeutics, Inc.

A precision gene editing biotechnology company

Industry

Biological Technology

Established Date

Listing Date

02/09/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

119

Fiscal Year Ends

12-31

Website

www.metagenomi.co

Security Type

Common stock

Office address

5959 Horton Street, 7th Floor, Emeryville, California 94608

Business

Introduction

Metagenomi Therapeutics, Inc., was originally formed in September 2016 and started its existing business as a Delaware limited liability company in 2018. The company is an in vivo gene editing company focused on the development of curative gene medicines using proprietary gene editing tools derived from metagenomics. Its wholly-owned lead project, MGX-001, aims to treat hemophilia A and continues to advance its R&D pipeline for genetic diseases through a variety of editing methods.

Company Financials

EPS

MGX has released its 2025 Q4 earnings. EPS was reported at -0.59, versus the expected -0.81, beating expectations. The chart below visualizes how MGX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MGX has released its 2025 Q4 earnings report, with revenue of 3.91M, reflecting a YoY change of -59.32%, and net profit of -22.53M, showing a YoY change of 3.72%. The Sankey diagram below clearly presents MGX's revenue sources and cost distribution.